Brinker Capital Investments’s Cytokinetics CYTK Stock Holding History

Brinker Capital Investments’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.45M	Buy	17,055 +8,122	+91%	+$583K	0.01%	965
2026 Q1	$589K	Sell	8,933 -2,700	-23%	-$172K	0.01%	1380
2025 Q4	$739K	Buy	11,633 +400	+4%	+$24.9K	0.01%	1399
2025 Q3	$617K	Buy	+11,233	New	+$463K	﹤0.01%	1459
2024 Q2	–	Sell	-3,168	Closed	-$222K	–	1727
2024 Q1	$222K	Buy	+3,168	New	+$245K	﹤0.01%	1577
2023 Q1	–	Sell	-4,847	Closed	-$222K	–	1576
2022 Q4	$222K	Sell	4,847 -34	-0.7%	-$1.46K	﹤0.01%	1264
2022 Q3	$236K	Sell	4,881 -2,595	-35%	-$125K	﹤0.01%	1214
2022 Q2	$294K	Buy	+7,476	New	+$301K	0.01%	1172
2022 Q1	–	Sell	-4,446	Closed	-$203K	–	1384
2021 Q4	$203K	Buy	+4,446	New	+$172K	﹤0.01%	1348

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brinker Capital Investments's CYTK Position: Q2 2026 in Review

Brinker Capital Investments increased its Cytokinetics (CYTK) stake by 91% in Q2 2026, buying an estimated $583K and bringing the position to 17,055 shares worth $1.45M. The position accounts for 0.01% of the portfolio, ranked #965.

Brinker Capital Investments first reported a position in CYTK in Q4 2021 and has held it in 9 quarters since. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Brinker Capital Investments held 17,055 shares of Cytokinetics worth $1.45M as of Q2 2026.
Brinker Capital Investments bought 8,122 Cytokinetics shares in Q2 2026, an estimated $583K.
Cytokinetics made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #965 holding.
Brinker Capital Investments first reported a position in Cytokinetics in Q4 2021 and has held it in 9 quarters since.
484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.